Thus, there is considerable similarity between breast and prostate tumour-initiating cells, and LNCaP CD44+CD24− cells provide a model system that may be useful in understanding the properties of these important tumour-initiating cells, whose underlying biology predicts poor clinical prognosis. This evidence concerns the gene CD44 and neoplasm.